pharmaphorum

SEPTEMBER 8, 2022

On the strength of phase 2 data, the FDA has awarded coveted breakthrough status to Pfizer’s vaccine against Group B Streptococcus (GBS), given to expectant mothers to prevent invasive infections in newborns and young infants. The post FDA gives Pfizer’s Group B strep vaccine breakthrough status appeared first on.

Vaccines 52

Vaccines FDA 52

PQA

JANUARY 12, 2024

Looking ahead, we are excited to announce dates for the 2024 Leadership Summit, as well as the 2025 and 2026 Annual Meetings. and in 2026, we'll be back in Baltimore. Save the dates for PQA's upcoming major meetings now through 2026! We know you have busy schedules and many meetings to attend throughout the year. Save the Dates!

Specialty Pharmacies 64

Specialty Pharmacies Vaccines 64

European Pharmaceutical Review

JULY 6, 2023

Further trials will be launching although most patients are expected to be enrolled from 2026 onwards. The Cancer Vaccine Launch Pad (CVLP), a new partnership led by NHS England, will create a database of eligible NHS cancer patients who will be offered the choice to take part in personalised cancer vaccine trials.

Vaccines 91

Vaccines 91

European Pharmaceutical Review

SEPTEMBER 22, 2023

Aseptic packaging eliminates the necessity for preservatives and refrigeration which is especially advantageous for medications and vaccines that are sensitive to temperature changes. Research Nester highlighted statistics which acknowledged that European production of pharmaceutical aseptic packaging is expected to reach $56 billion by 2026.

Packaging 89

Packaging Vaccines Compounding 89

Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Additionally, Merck has signed patent litigation settlement deals with various generic firms, permitting them to offer generic versions of Januvia and Janumet to the US market in May 2026, or before under specific conditions.

FDA 69

FDA Vaccines 69

pharmaphorum

SEPTEMBER 30, 2022

That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No. Viatris could still take its cases further, but for now Merck has retained market exclusivity for Januvia, Janumet, and Janumet XR until at least 2026. billion in the first half of 2022.

Vaccines 57

Vaccines FDA 57

Pharmaceutical Technology

JULY 28, 2022

Tuas Biomedical Park New Vaccine Production Facility – $467m. The project involves the construction of a new vaccine production facilities at Tuas Biomedical Park in Singapore. Construction work started in Q2 2022 and is expected to be completed in Q1 2026. Yeosu Mononitrobenzene Manufacturing Plant – $375m.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

JULY 28, 2022

Tuas Biomedical Park New Vaccine Production Facility – $467m. The project involves the construction of a new vaccine production facilities at Tuas Biomedical Park in Singapore. Construction work started in Q2 2022 and is expected to be completed in Q1 2026. Yeosu Mononitrobenzene Manufacturing Plant – $375m.

Vaccines 40

Vaccines 40

pharmaphorum

APRIL 29, 2022

The healthy sales increase was bolstered by the timing of orders for AZ’s COVID-19 vaccine Vaxzevria , which made $1.1 “Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation,” he added.

Vaccines 102

Vaccines 102

pharmaphorum

APRIL 21, 2022

Overall spending on medicines rose 12% in 2021 to $407 billion, driven by a $29 billion spend on COVID-19 vaccines and medicines. Prescription drug use in the US soared last year, as might be expected during a pandemic, but is expected to fall back sharply in 2023, according to IQVIA’s latest report on the sector.

Vaccines 52

Vaccines 52

pharmaphorum

OCTOBER 28, 2021

The Association of the British Pharmaceutical Industry (ABPI) and BioIndustry Association (BIA) both said that the increase acknowledges the enormous contribution made by the life sciences sector in helping to limit the impact of the pandemic through the rapid development of diagnostics, drugs and vaccines.

Vaccines 98

Vaccines 98

pharmaphorum

FEBRUARY 7, 2022

The approval is some relief for Sanofi after a crop of pipeline disappointments last year, with Evaluate estimating the drug could make more than $500 million in sales in 2026. It also abandoned an mRNA-based vaccine for COVID-19 and suffered delays to another COVID-19 shot partnered with GlaxoSmithKline.

FDA 52

FDA Labelling Immunization Vaccines 52

pharmaphorum

JANUARY 29, 2023

Think about recent technological breakthroughs such as mRNA vaccines and the potential for mRNA-based therapeutics, or the recent ramp up in vaccine production facilities – to name just a few examples. That’s what is relentlessly driving industry growth, as well as spurring innovation and efficiency.

Nursing Homes 85

Nursing Homes Hospitals Vaccines 85

pharmaphorum

JULY 1, 2021

Along with the appointment of new non-executive directors, Elliott would like to see a moratorium on profit and revenue-related bonuses unless management meets its 2026 targets of 5% profit growth and 10% turnover growth and raising the margin target from 30% to 32%.

Vaccines 52

Vaccines 52

ISPE

SEPTEMBER 29, 2023

For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Takeda has reduced CO2 emission by 861 tons.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Patient Care 52

pharmaphorum

JANUARY 21, 2022

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. There is no easy answer to the question of how to incentivise innovation without restricting access.

Insurance 52

Insurance Vaccines 52

PharmaShots

FEBRUARY 21, 2023

threshold by 2026. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

pharmaphorum

NOVEMBER 6, 2022

The new drug will reach the market ahead of RSV vaccines that are designed to protect newborns in the months after birth by vaccinating expectant mothers, who pass on antibodies against the virus in the womb. AZ and Sanofi say they hope to launch the antibody next autumn, in time for the 2023/24 RSV season.

Vaccines 62

Vaccines Labelling 62

pharmaphorum

JUNE 15, 2021

New Science is projected to drive 81% of biopharma revenue growth and 61% of all revenues between 2021 and 2026, outpacing our previous forecast of 54% of all revenues from 2017-2022. And we expect a 69% higher average net present value (NPV) for New Science treatments versus traditional counterparts from 2022—2026.

Vaccines 89

Vaccines 89

European Pharmaceutical Review

AUGUST 22, 2022

They noted that while production of COVID-19 pandemic vaccines and therapeutics is currently absorbing much of the flexible capacity available in the industry, but said that as demand moderates, capacity will normalise enabling other products to be prioritised.

Vaccines 83

Vaccines 83

The FDA Law Blog

DECEMBER 3, 2023

On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. covered insulin product or vaccine). Manufacturers must sign the agreement by March 1, 2024, to participate in the 2025 plan year.

Labelling 105

Labelling Compounding Payment Processing Vaccines 105

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth.

HIV Treatment and Prevention Agents 57

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 57

pharmaphorum

JANUARY 6, 2022

IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies 93

The FDA Law Blog

AUGUST 14, 2022

The number will begin in 2026 with 10 drug covered under Medicare Part D and will increase annually to 20 Part B and 20 Part D drugs by 2029 and thereafter, with the selected drugs accumulating from year to year. The same will be required under state Medicaid and CHIP programs by October 1, 2023.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

OCTOBER 21, 2020

Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar 13, with two new phase 3 trials backing its rival shot V114. It reiterated its plans to file for approval of the vaccine before the end of the year in the US.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

FEBRUARY 16, 2022

The Life Sciences Vision also identified seven therapeutic areas that are priorities for the government: treatments for neurodegenerative disorders, cancer immunotherapies, novel vaccines, cardiometabolic therapies, treatments for respiratory disorders, therapies for multi-system ageing and treatments for mental illness.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

MAY 25, 2023

Analysis estimates that the oncolytic virus market will reach $1 billion by 2026. Transgene will be presenting new data at ASCO 2023 for its therapeutic cancer vaccines TG4001, in Phase II study in patients with HPV16-positive anogenital tumours ( NCT03260023 ), and TG4050, Phase I study in head and neck cancers ( NCT04183166 ).

Labelling 52

Labelling Communication Vaccines 52

BuzzRx

AUGUST 30, 2022

The Inflation Reduction Act will allow the government to negotiate lower prescription drug costs for some of the highest-priced, covered drugs between 2026 and 2029 and beyond. million who received the shingles vaccine. These are mainly drugs for which generic or biosimilar competitors are not available.

Vaccines 52

Vaccines Insurance Packaging Immunization 52